Chan myae htut

•Descargar como PPT, PDF•

0 recomendaciones•338 vistas

zawhtet1984

Educación

Moscow State University Faculty of Basic Medicine Presented by Dr.Chan Myae Htut (M.B.B.S) Supervisors – Prof Dr. B.I.Polyakov,Dr.D.A.Bykov May 19,2010 CHOP CHEMOTHERAPY PLUS RITUXIMAB COMPARED WITH CHOP ALONE IN ELDERY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA

INTRODUCTION ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

ETIOLOGY AND PATHOGENESIS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

CLINICAL FEATURES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

DIAGNOSIS ,[object Object],[object Object],[object Object],[object Object]

Therapy(In patients older than 60 years) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

OBJECTIVE OF STUDY ,[object Object],[object Object]

DESIGN OF STUDY 52 PATIENTS 27 PATIENTS R-CHOP 25 PATIENTS CHOP 27 PATIENTS R-CHOP

MAIN CHARACTERISTICS OF PATIENTS (N=52) CHARACTERISTICS R-CHOP (N=27) NO(%) CHOP (N=25) NO(%) Age <65 yrs 65 – 69 yrs 70 -74 yrs > 74 yrs 6 (22) 8 (28) 7 (26) 6 (22) 6 (24) 8 (31) 7 (28) 4 (16) Male Sex 12 (46) 16 (54) Performance Status 0 1 > 1 9 (33) 12 (45) 6 (22) 9 (36) 12 (48) 4 (17) B symptoms 11 (39) 9 (36) Stage I II III IV 0 5 (20) 4 (16) 18 (63) 0 5 (20) 4 (15) 16 (65)

MAIN CHARACTERISTICS OF PATIENTS (N=52) (Contd.) CHARACTERISTICS R-CHOP (N=27) NO(%) CHOP (N=25) NO (%) No of extra nodal sites 0 1 >2 6 (23) 13 (47) 8 (30) 6 (22) 12 (52) 7 (26) Bulky tumour (>10cm) 8 (30) 8 (32) Bone marrow involvement 8 (30) 7 (28) Standard International Prognostic Index Score 0-1 2 3 4-5 4 (16) 9 (32) 11 (39) 3 (15) 3 (12) 9 (35) 10 (42) 3 (12)

RESPONSE TO TREATMENT RESPONSE R-CHOP (N=27) NO(%) CHOP (N=25) NO(%) Complete response Unconfirmed complete response Partial response Progressive disease Death without progression 14 (52) 6 (23) 2 (7) 3 (9) 2 (6) 9 (37) 7 (26) 2 (6) 5 (22) 2 (1)

DISCUSSION ,[object Object],[object Object],[object Object]

CONCLUSION ,[object Object],[object Object]

Más contenido relacionado

La actualidad más candente

Biochemical and cellular implications of drug resistant malariaGloria Okenze

An evaluation of the clinical utility of a panel of variants in DPYD and ENOS...Oxford Cancer Biomarkers

3 gvt effectYohannis Asefa

Discoidin receptors a proteomic portretMaciej Luczynski

Ong et al._Translational utility of next-generation sequencing_2013_GenomicsFrank Ong, MD, CPI

ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positi...European School of Oncology

Dr. David Mooney - Simposio Internacional 'Terapias oncológicas avanzadas'Fundación Ramón Areces

The Potent ALK Inhibitor Brigtanib (AP26613) Overcomes Mechanisms of Resistan...Md.Tanvir Hossain Bhuiyan

ncomms11428Brian Yard

Ideal induction therapy for newly diagnosed AML. Do we have a consensus?spa718

Prognostic and clinicopathological significance of programmed death ligand 1 ...Clinical Surgery Research Communications

npjsba201634-2Birgit Schoeberl

Necitumumab imc 11 f8 ott 20103s4num

The Prognostic Value of Nucleolar Organiser Regions in Colorectal CancerMichelle Fynes

Metanalisysjuandavidpuertas

Clinical Cancer Research PublicationDavid W. Salzman

genomics upenn publication 1Eyas Mukhtar, MBA-HCM

Risk Factors for Fluconzaole Resistance in Patients with Candida Glabrata 10....Leonard Davis Institute of Health Economics

Hitting the Bullseye: Are Cell Penetrating Peptides (CPP) the Future of Targe...CrimsonpublishersCancer

Vorinostat combined with DNMTi epigenetically controls the proliferation of l...MustafaFathy6

La actualidad más candente (20)

Biochemical and cellular implications of drug resistant malaria

An evaluation of the clinical utility of a panel of variants in DPYD and ENOS...

3 gvt effect

Discoidin receptors a proteomic portret

Ong et al._Translational utility of next-generation sequencing_2013_Genomics

ABC1 - R. Wuerstlein - Primary tumor in breast cancer and phenotype in positi...

Dr. David Mooney - Simposio Internacional 'Terapias oncológicas avanzadas'

The Potent ALK Inhibitor Brigtanib (AP26613) Overcomes Mechanisms of Resistan...

ncomms11428

Ideal induction therapy for newly diagnosed AML. Do we have a consensus?

Prognostic and clinicopathological significance of programmed death ligand 1 ...

npjsba201634-2

Necitumumab imc 11 f8 ott 2010

The Prognostic Value of Nucleolar Organiser Regions in Colorectal Cancer

Metanalisys

Clinical Cancer Research Publication

genomics upenn publication 1

Risk Factors for Fluconzaole Resistance in Patients with Candida Glabrata 10....

Hitting the Bullseye: Are Cell Penetrating Peptides (CPP) the Future of Targe...

Vorinostat combined with DNMTi epigenetically controls the proliferation of l...

Destacado

Bedrijfspresentatie R&S MulticleaningRScleaning

Українська онлайн спільнотаbohdan tarlupa

Mazanick final presentation mariaksandberg

Congresso SIGO 2011| L'età conquistata dalla donnaVieri Boncinelli

Yehlaingbwarzawhtet1984

Eat more greensguest85ca4364

Dlt storyboard 5.17.10mariaksandberg

Seo Ranking Factorsbohdan tarlupa

Ppt For Bitlswvivian

Infokost promo mei_july_2010Eta Maryani

Over customguestb9e7ce0

Lesson Plan For IITlswvivian

Pyae phyo aung's thesis (breast cancer)zawhtet1984

Formazione in sessuologiaVieri Boncinelli

L'endometriosi una ferita all'identità sessuale femminileVieri Boncinelli

'S artistic gmpd supplementary code of points 10 february 2010 (1)EmmaHJ

La contraccezioneVieri Boncinelli

Educazione sessualeVieri Boncinelli

Destacado (18)

Bedrijfspresentatie R&S Multicleaning

Українська онлайн спільнота

Mazanick final presentation

Congresso SIGO 2011| L'età conquistata dalla donna

Yehlaingbwar

Eat more greens

Dlt storyboard 5.17.10

Seo Ranking Factors

Ppt For Bit

Infokost promo mei_july_2010

Over custom

Lesson Plan For IIT

Pyae phyo aung's thesis (breast cancer)

Formazione in sessuologia

L'endometriosi una ferita all'identità sessuale femminile

'S artistic gmpd supplementary code of points 10 february 2010 (1)

La contraccezione

Educazione sessuale

Similar a Chan myae htut

Cco clin onc_june _2012_lymphoma_slidesAdonis Guancia

Hodgkin’S And Non Hodgkin’S Lymphomafondas vakalis

DLBCL- Recent Molecular Classification.pptxroysudip900

Powerpoint presentation by dr sathihazawhtet1984

Dr. Manuel Hidalgo - Simposio Internacional ' Terapias oncológicas avanzadas'Fundación Ramón Areces

Roschewski-Mark-IV-hematology_forum_2016EAFO2014

V_Hematology_Forum_B_AfanasievEAFO1

Bendamustine Vs R-CHOP/R-CVP-Bright studySeth g s medical college and kem hospital mumbai

Lupus Nephritis Dilemma - Prof. Mohsen El KosiMNDU net

Building Bridges Between Discovery, Preclinical, And Clinical Research 2008tsornasse

LLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patientsEuropean School of Oncology

Ohio State's ASH Review 2017 - Myeloproliferative DisordersOSUCCC - James

New Treatments for Lupus by Daniel J. Wallace, MDLupusNY

S.c.l.c dr.hatemhatem honor

The Role of Radiotherapy in the Treatment of Early Stage Ocular Marginal Zone...daranisaha

Lenalidomide maintenance compared with placebo in responding elderlyravi jaiswal

7 neelapuspa718

A. Stathis - New drugs in the treatment of lymphomasEuropean School of Oncology

Antibiotic prophylaxis in sever Acute PanceriatitisSaeed Al-Shomimi

Update on treatment for lymphoma, Lymphoma Support Ireland meeting - feb 2011...Lymphoma Support Ireland

Similar a Chan myae htut (20)

Cco clin onc_june _2012_lymphoma_slides

Hodgkin’S And Non Hodgkin’S Lymphoma

DLBCL- Recent Molecular Classification.pptx

Powerpoint presentation by dr sathiha

Dr. Manuel Hidalgo - Simposio Internacional ' Terapias oncológicas avanzadas'

Roschewski-Mark-IV-hematology_forum_2016

V_Hematology_Forum_B_Afanasiev

Bendamustine Vs R-CHOP/R-CVP-Bright study

Lupus Nephritis Dilemma - Prof. Mohsen El Kosi

Building Bridges Between Discovery, Preclinical, And Clinical Research 2008

LLA 2011 - J.M. Vose - Treatment of lymphomas in elderley patients

Ohio State's ASH Review 2017 - Myeloproliferative Disorders

New Treatments for Lupus by Daniel J. Wallace, MD

S.c.l.c dr.hatem

The Role of Radiotherapy in the Treatment of Early Stage Ocular Marginal Zone...

Lenalidomide maintenance compared with placebo in responding elderly

7 neelapu

A. Stathis - New drugs in the treatment of lymphomas

Antibiotic prophylaxis in sever Acute Panceriatitis

Update on treatment for lymphoma, Lymphoma Support Ireland meeting - feb 2011...

Más de zawhtet1984

Tanl power pointzawhtet1984

Kyaw thura zawzawhtet1984

Zaw htetzawhtet1984

Sithu kozawhtet1984

Khant zaw aungzawhtet1984

Aung thiha soezawhtet1984

Aung myo zaw(nutrition in preterm and congenital hypotrophy)zawhtet1984

Aung citt nyeinzawhtet1984

Más de zawhtet1984 (8)

Tanl power point

Kyaw thura zaw

Zaw htet

Sithu ko

Khant zaw aung

Aung thiha soe

Aung myo zaw(nutrition in preterm and congenital hypotrophy)

Aung citt nyein

Último

How to do quick user assign in kanban in Odoo 17 ERPCeline George

Global Lehigh Strategic Initiatives (without descriptions)cama23

Karra SKD Conference Presentation Revised.pptxAshokKarra1

ANG SEKTOR NG agrikultura.pptx QUARTER 4MiaBumagat1

AUDIENCE THEORY -CULTIVATION THEORY - GERBNER.pptxiammrhaywood

Earth Day Presentation wow hello nice greatYousafMalik24

Choosing the Right CBSE School A Comprehensive Guide for Parentsnavabharathschool99

How to Add Barcode on PDF Report in Odoo 17Celine George

USPS® Forced Meter Migration - How to Know if Your Postage Meter Will Soon be...Postal Advocate Inc.

Active Learning Strategies (in short ALS).pdfPatidar M

Difference Between Search & Browse Methods in Odoo 17Celine George

4.18.24 Movement Legacies, Reflection, and Review.pptxmary850239

YOUVE GOT EMAIL_FINALS_EL_DORADO_2024.pptxConquiztadors- the Quiz Society of Sri Venkateswara College

Transaction Management in Database Management SystemChristalin Nelson

INTRODUCTION TO CATHOLIC CHRISTOLOGY.pptxHumphrey A Beña

Virtual-Orientation-on-the-Administration-of-NATG12-NATG6-and-ELLNA.pdfErwinPantujan2

Keynote by Prof. Wurzer at Nordex about IP-designMIPLM

Incoming and Outgoing Shipments in 3 STEPS Using Odoo 17Celine George

YOUVE_GOT_EMAIL_PRELIMS_EL_DORADO_2024.pptxConquiztadors- the Quiz Society of Sri Venkateswara College

Influencing policy (training slides from Fast Track Impact)Mark Reed

Chan myae htut

1. Moscow State University Faculty of Basic Medicine Presented by Dr.Chan Myae Htut (M.B.B.S) Supervisors – Prof Dr. B.I.Polyakov,Dr.D.A.Bykov May 19,2010 CHOP CHEMOTHERAPY PLUS RITUXIMAB COMPARED WITH CHOP ALONE IN ELDERY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA

9. DESIGN OF STUDY 52 PATIENTS 27 PATIENTS R-CHOP 25 PATIENTS CHOP 27 PATIENTS R-CHOP

10.

11. MAIN CHARACTERISTICS OF PATIENTS (N=52) CHARACTERISTICS R-CHOP (N=27) NO(%) CHOP (N=25) NO(%) Age <65 yrs 65 – 69 yrs 70 -74 yrs > 74 yrs 6 (22) 8 (28) 7 (26) 6 (22) 6 (24) 8 (31) 7 (28) 4 (16) Male Sex 12 (46) 16 (54) Performance Status 0 1 > 1 9 (33) 12 (45) 6 (22) 9 (36) 12 (48) 4 (17) B symptoms 11 (39) 9 (36) Stage I II III IV 0 5 (20) 4 (16) 18 (63) 0 5 (20) 4 (15) 16 (65)

12. MAIN CHARACTERISTICS OF PATIENTS (N=52) (Contd.) CHARACTERISTICS R-CHOP (N=27) NO(%) CHOP (N=25) NO (%) No of extra nodal sites 0 1 >2 6 (23) 13 (47) 8 (30) 6 (22) 12 (52) 7 (26) Bulky tumour (>10cm) 8 (30) 8 (32) Bone marrow involvement 8 (30) 7 (28) Standard International Prognostic Index Score 0-1 2 3 4-5 4 (16) 9 (32) 11 (39) 3 (15) 3 (12) 9 (35) 10 (42) 3 (12)

13. RESPONSE TO TREATMENT RESPONSE R-CHOP (N=27) NO(%) CHOP (N=25) NO(%) Complete response Unconfirmed complete response Partial response Progressive disease Death without progression 14 (52) 6 (23) 2 (7) 3 (9) 2 (6) 9 (37) 7 (26) 2 (6) 5 (22) 2 (1)

14. EVENT FREE SURVIVAL

15. OVERALL SURVIVAL

16. NONHEMATOLOGIC ADVERSE EVENTS

17. NONHEMATOLOGIC ADVERSE EVENTS(Contd.)

18.

19.

20.